Avidity's Stock Jumps 3% Following Takeover Approach Report

Avidity Biosciences' stock jumped 3% to $39.47 after a report by FT that the company received a takeover approach. The report did not disclose the identity of the potential buyer or the terms of the offer. Avidity is a biotech company that focuses on developing RNA-targeting therapies for diseases. The news of the potential takeover has likely boosted investor confidence in the company's prospects.

Avidity Biosciences' stock surged 18% to $39.47 on Wednesday, following a report by the Financial Times that the company had received a potential takeover offer [1]. The report, citing unnamed sources familiar with the matter, stated that Swiss pharmaceutical giant Novartis (NYSE: NVS) had approached Avidity about a possible acquisition. The discussions are reportedly in the early stages, and there is no guarantee that a deal will materialize.

Avidity Biosciences focuses on developing RNA-targeting therapies for various diseases. The news of the potential takeover has likely boosted investor confidence in the company's prospects. The stock of Dyne Therapeutics (NASDAQ: DYN), another company operating in a similar space, also jumped 18% on Wednesday following the report.

Novartis has been actively reshaping its portfolio in recent years, focusing on high-growth areas including rare diseases. Any potential acquisition of Avidity would align with this strategy, potentially strengthening Novartis’s position in the rare disease treatment market.

References:
[1] https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-weighs-deal-biotech-avidity-biosciences-ft-reports-2025-08-06/
[2] https://www.investing.com/news/stock-market-news/avidity-biosciences-stock-soars-on-novartis-takeover-approach-report-4173978